Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710793 | 0.88 | HTR1A (0.44) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL5937368 | 0.87 | DRD2 (0.50) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL6784310 | 0.86 | HTR1A (0.45) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL5899843 | 0.86 | ADRA1D (0.45) | HTR1A | |
| SCHEMBL5899905 | 0.83 | S1PR5 (0.46) | DRD2 | |
| SCHEMBL6710913 | 0.82 | DRD3 (0.49) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL5899901 | 0.76 | ENPP2 (0.46) | HTR1A | |
| SCHEMBL5899888 | 0.74 | SLC6A2 (0.62) | HTR1A | |
| SCHEMBL6709071 | 0.73 | HTR1A (0.53) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL5937286 | 0.71 | HTR1A (0.51) | DRD2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | LDLR, NR1H2, NR1H3 | DRD2 573/4885HTR1A 1425/4885DRD3 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.